Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

seekingalpha.com - Wall Street Week Ahead - Apple Leads Packed Earnings Calendar As Investors Eye Tech, Pharma Results
Apple Leads Packed Earnings Calendar As Investors Eye Tech, Pharma Results
Seeking Alpha –

Get ahead of the market by subscribing to Seeking Alpha's Wall Street Week Ahead, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs…

swissinfo.ch - swissinfo.ch - Lawyer urges probe into Crans-Montana finances
Lawyer urges probe into Crans-Montana finances
www.swissinfo.ch –

WHO candidate Hanan Balkhy: ‘The bottom line is that the funding is slimmer' Read more: WHO candidate Hanan Balkhy: ‘The bottom line is that the funding is slimmer' Swiss components also found in new Russian weapons Read more: Swiss…

marketbeat.com - NewAmsterdam Pharma (NASDAQ:NAMS) Raised to Hold at Wall Street Zen
NewAmsterdam Pharma (NASDAQ:NAMS) Raised to Hold at Wall Street Zen
MarketBeat –

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) was upgraded by research analysts at Wall Street Zen from a 'sell' rating to a 'hold' rating in a report released on Sunday, Wall Street Zen reports. A number of other brokerages have also…

marketbeat.com - Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG) Sees Large Increase in Short Interest
Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG) Sees Large Increase in Short Interest
MarketBeat –

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) was the recipient of a significant increase in short interest in the month of October. As of October 15th, there was short interest totaling 18,161 shares, an…

marketbeat.com - NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Stock Has Average Target Price of $48.90 According to Analysts
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Stock Has Average Target Price of $48.90 According to Analysts
MarketBeat –

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) has been assigned an average recommendation of 'Moderate Buy' from the twelve ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research…

fool.com - Adria Cimino - After Eli Lilly's Explosive Earnings Report, Is It Too Late to Buy the Stock?
After Eli Lilly's Explosive Earnings Report, Is It Too Late to Buy the Stock?
The Motley Fool –

Eli Lilly (LLY +3.19%), as a pharma giant, offers investors a certain sense of safety in any market environment. This is because, at all times, patients need their medical treatments. But this company has also presented investors with a spectacular…

fool.com - Motley Fool Transcribing - Aptar (ATR) Q3 2026 Earnings Call Transcript
Aptar (ATR) Q3 2026 Earnings Call Transcript
The Motley Fool –

Senior Vice President, Investor Relations and Communications - Mary Skafidas President and CEO - Gael Touya Executive Vice President and CFO - Vanessa Kanu Reported Sales -- $1.02 billion, representing a 6% increase driven by broad-based growth…

birminghammail.co.uk - James Rodger - Heart medication urgently recalled with pharmacists told to 'stop supplying
Heart medication urgently recalled with pharmacists told to 'stop supplying
Birmingham Live –

Heart medication is being urgently recalled in the UK with pharmacists told to “stop supplying immediately”. A batch of the oral solution of clopidogrel from Xeal Pharma has been recalled, according to the Medicines and Healthcare…

ndtv.com - Abhinav Singh - Indian Biotech Startup Claims To Offer Personalised Cancer Vaccines
Indian Biotech Startup Claims To Offer Personalised Cancer Vaccines
NDTV –

PopVax launches RNA Foundry to develop personalised cancer vaccines using mRNA technology. Summary is AI-generated, newsroom-reviewed PopVax launched RNA Foundry to develop personalised cancer vaccines in Hyderabad The facility uses mRNA technology…

pakobserver.net - Web Desk Lahore - A look at Top Stocks at PSX as Market ends October 2026 in Red
A look at Top Stocks at PSX as Market ends October 2026 in Red
Pakistan Observer –

KARACHI – Pakistan Stock Exchange (PSX) wrapped up October 2026 under pressure, with investors witnessing turbulent trading session as the benchmark KSE-100 Index lost 784 points on Friday, October 30, wiping out part of the gains…

marketbeat.com - Top Growth Stocks To Watch Now - October 31st
Top Growth Stocks To Watch Now - October 31st
MarketBeat –

Could Falling Yields Make REIT Stocks Worth a Second Look? Prologis, Teledyne Technologies, Ascendis Pharma A/S, Digital Turbine, and Jersey Mike's are the five Growth stocks to watch today, according to MarketBeat's stock screener tool. Growth…

thehindubusinessline.com - Nishanth  Gopalakrishnan - Big Story: Anthropic's IPO and the most defining months ahead in stock market history
Big Story: Anthropic's IPO and the most defining months ahead in stock market history
The HinduBusinessLine –

Nevertheless, here's a summary of Anthropic's business, things going for it and those that are not. Anthropic, founded in 2021, is an AI research lab that develops frontier AI models and lets customers use them for a consideration. Its products…

thenyledger.com - Press Room - Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs
Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs
The New York Ledger –

In a cavernous office in London's AI hub, a group of researchers is preparing to do battle with humanity's oldest enemy. Isomorphic Labs, a spinoff of Google DeepMind and the brainchild of AI pioneer Demis Hassabis, has an ambitious mission even by…

thenyledger.com - Press Room - Anthropic's next big AI business is life sciences, from biotech research to drug discovery
Anthropic's next big AI business is life sciences, from biotech research to drug discovery
The New York Ledger –

Anthropic conquered coding. Now it's setting its sights on the human body. Anthropic's S-1 filing, which outlines its ambitions and financials ahead of a massive initial public offering next month, reads as a life-sciences manifesto. The maker of…

marketbeat.com - 25,747 GSK PLC Sponsored ADR $GSK Shares Acquired by Summit Global Investments
25,747 GSK PLC Sponsored ADR $GSK Shares Acquired by Summit Global Investments
MarketBeat –

Summit Global Investments grew its position in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 123.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The…

Receive a Daily briefing on Pharma Industry News

Get Started